EcoDrugPlus

Potassium Voltage-Gated Channel Subfamily A Member 5

Ensembl ID : ENSAPOG00000023382
Gene Symbol: KCNA5
4 Cross references
170 Possible Orthologues:

Potassium Voltage-Gated Channel Subfamily D Member 3

Ensembl ID : ENSAPOG00000021043
Gene Symbol: KCND3
2 Cross references
190 Possible Orthologues:

Potassium Voltage-Gated Channel Subfamily H Member 2

Ensembl ID : ENSAPOG00000020799
Gene Symbol: KCNH2
3 Cross references
186 Possible Orthologues:

Potassium Voltage-Gated Channel Subfamily Kqt Member 2-Like

Ensembl ID : ENSAPOG00000001704
Gene Symbol: LOC110962966
3 Cross references
184 Possible Orthologues:

Potassium Voltage-Gated Channel Subfamily Q Member 2

Ensembl ID : ENSAPOG00000019795
Gene Symbol: KCNQ2
4 Cross references
184 Possible Orthologues:

Potassium Voltage-Gated Channel Subfamily Q Member 3

Ensembl ID : ENSAPOG00000016922
Gene Symbol: KCNQ3
3 Cross references
193 Possible Orthologues:

Potassium Voltage-Gated Channel Subfamily Q Member 5

Ensembl ID : ENSAPOG00000001680
Gene Symbol: KCNQ5
3 Cross references
200 Possible Orthologues:

Potassium Voltage-Gated Channel, Shal-Related Subfamily, Member 3

Ensembl ID : ENSAPOG00000017070
Gene Symbol: KCND3
1 Cross references
194 Possible Orthologues:

Presenilin Enhancer, Gamma-Secretase Subunit

Ensembl ID : ENSAPOG00000020997
Gene Symbol: PSENEN
3 Cross references
185 Possible Orthologues:

Presenilin-1-Like

Ensembl ID : ENSAPOG00000003991
Gene Symbol: LOC110967531
3 Cross references
202 Possible Orthologues:

Presenilin-2-Like

Ensembl ID : ENSAPOG00000008472
Gene Symbol: LOC110965232
3 Cross references
206 Possible Orthologues:

Probable Histone Deacetylase 1-B

Ensembl ID : ENSAPOG00000002698
Gene Symbol: LOC110954112
3 Cross references
250 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).